Table 4 CRP plasma levels in COVID-19 ICU patients: it shows differences between survivors and non-survivors for CRP plasma level each time points with Wilcoxon sign rank test, Two-way ANOVA during the time, mixed model coefficients, and Area Under the Receiving Operator sensitivity and specificity for the primary outcome
From: Point-of-care pancreatic stone protein measurement in critically ill COVID-19 patients
CRP mg/dl | T0 (21 patients survived) | T1 (21 patients survived) | T2 (21 patients survived) | T3 (21 patients survived) |
|---|---|---|---|---|
Survivors (mean ± st. dev) | 9.88 ± 7.34 | 5.01 ± 6.49 | 2.01 ± 3.16 | 1.60 ± 2.53 |
Nonsurvivors (mean ± st. dev) | 8.37 ± 8.04 | 8.05 ± 9.26 | 4.98 ± 5.57 | 6.03 ± 7.74 |
P | 0.5817 | 0.6075 | 0.1738 | 0.2177 |
| Â | Â | Â | Two-way ANOVA | P 0.1394 |
| Â | CRP | Mortality | Timing | Cons |
Correlation coefficient (Rrm) | 5.60 | 2.15 | -0.92 | 8.18 |
P |  < 0.001* | 0.127 |  < 0.001* |  < 0.001* |
| Â | T0 | T1 | T2 | T3 |
AUROC | 0.5769 | 0.5729 | 0.6823 | 0.6615 |
P value | 0.645 | 0.394 | 0.151 | 0.119 |
Sensitivity | 0.00% | 25.00 | 37.50 | 37.50 |
Specificity | 100.00% | 83.33% | 83.33% | 91.67% |
Positive predictive value | 0.00% | 50.00% | 60.00% | 75.00% |
Negative predictive value | 61.90% | 62.50% | 66.67% | 68.75% |
Correctly classified | 61.90% | 60.00% | 65.00% | 70.00% |